Evidence map›Paper›PMID 30744170›Full record

ArticleCancers2019

SYK Inhibition Potentiates the Effect of Chemotherapeutic Drugs on Neuroblastoma Cells in Vitro.

Conny Tümmler, Gianina Dumitriu, Malin Wickström, Peter Coopman, Andrey Valkov, Per Kogner, John Inge Johnsen, Ugo Moens, Baldur Sveinbjörnsson

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancers, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.6field-weighted citation impact, top 32% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 7 citations in OpenAlex.

  1. New insights into SYK targeting in solid tumors.Trends in pharmacological sciences · 2024
    Review
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 4 institutions in 3 countries.

Conny TümmlerMolecular Inflammation Research Group, Department of Medical Biology, Faculty of Health Sciences, UiT The Arctic University of Norway, Hansine Hansens veg 18, 9019 Tromsø, Norway. conny.tummler@uit.no.ORCID 0000-0002-5530-4752
Gianina DumitriuMolecular Inflammation Research Group, Department of Medical Biology, Faculty of Health Sciences, UiT The Arctic University of Norway, Hansine Hansens veg 18, 9019 Tromsø, Norway. gianina.dumitriu@uit.no.
Malin WickströmChildhood Cancer Research Unit, Department of Women's and Children's Health, Karolinska Institutet, Tomtebodav 18A, 17177 Stockholm, Sweden. Malin.Wickstrom@ki.se.
Peter CoopmanIRCM, Inserm U1194, Université Montpellier, ICM, Institut régional du Cancer Montpellier, Campus Val d'Aurelle, 208 Rue des Apothicaires, 34298 Montpellier Cedex 5, France. peter.coopman@inserm.fr.
Andrey ValkovDepartment of Clinical Pathology, University Hospital of Northern Norway, Sykehusveien 38, 9019 Tromsø, Norway. andrej.yurjevic.valkov@unn.no.
Per KognerChildhood Cancer Research Unit, Department of Women's and Children's Health, Karolinska Institutet, Tomtebodav 18A, 17177 Stockholm, Sweden. Per.Kogner@ki.se.
John Inge JohnsenChildhood Cancer Research Unit, Department of Women's and Children's Health, Karolinska Institutet, Tomtebodav 18A, 17177 Stockholm, Sweden. John.Inge.Johnsen@ki.se.
Ugo MoensMolecular Inflammation Research Group, Department of Medical Biology, Faculty of Health Sciences, UiT The Arctic University of Norway, Hansine Hansens veg 18, 9019 Tromsø, Norway. ugo.moens@uit.no.
Baldur SveinbjörnssonMolecular Inflammation Research Group, Department of Medical Biology, Faculty of Health Sciences, UiT The Arctic University of Norway, Hansine Hansens veg 18, 9019 Tromsø, Norway. baldur.sveinbjornsson@uit.no.
Karolinska Institutet · SEUiT The Arctic University of Norway · NOInserm · FRUniversity Hospital of North Norway · NO

Funding

Barncancerfonden N/AErna and Olav Aakre Foundation for Cancer Research A20310Institut National du Cancer N/APlan Cancer ASC14021FSARadiumhemmets Forskningsfonder N/ASwedish Cancer Foundation N/ASwedish Foundation for Strategic Research N/ASwedish Research Council N/AThe Norwegian Childhood Cancer Society N/AUniversitetet i Tromsø N/A
6 · The paper itself

Abstract

Neuroblastoma is a malignancy arising from the developing sympathetic nervous system and the most common and deadly cancer of infancy. New therapies are needed to improve the prognosis for high-risk patients and to reduce toxicity and late effects. Spleen tyrosine kinase (SYK) has previously been identified as a promising drug target in various inflammatory diseases and cancers but has so far not been extensively studied as a potential therapeutic target in neuroblastoma. In this study, we observed elevated

Indexed as

combination therapyneuroblastomapediatric cancertyrosine kinase

Identifiers

PMID30744170
PMCPMC6406899
OpenAlexW2912424604

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.